4//SEC Filing
bluebird bio, Inc. 4
Accession 0001209191-17-011322
CIK 0001293971operating
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 8:17 AM ET
Size
12.8 KB
Accession
0001209191-17-011322
Insider Transaction Report
Form 4
Mandell James
Director
Transactions
- Exercise/Conversion
Common Stock
2017-02-14$25.16/sh+1,950$49,062→ 6,950 total - Exercise/Conversion
Stock Option (right to buy)
2017-02-14+1,950→ 5,550 totalExercise: $25.16Exp: 2024-06-11→ Common Stock (1,950 underlying) - Exercise/Conversion
Stock Option (right to buy)
2017-02-14+4,000→ 0 totalExercise: $21.43Exp: 2024-01-08→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2017-02-14$21.43/sh+4,000$85,720→ 5,000 total - Sale
Common Stock
2017-02-14$80.01/sh−5,950$476,076→ 1,000 total
Footnotes (4)
- [F1]This sales reported in the Form 4 were effectd pursuant to a 10b5-1 trading plan adopted by the reporting person on December 13, 2016.
- [F2]The range in prices for the transaction reported on this line was $80.00 to $80.15. The average weighted price was $80.0128. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]This option vests ratably over three years in annual installments, commencing on January 8, 2014.
- [F4]This option vests 100% on the earlier of June 11, 2015 or the date of the next annual meeting of stockholders.
Documents
Issuer
bluebird bio, Inc.
CIK 0001293971
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001293971
Filing Metadata
- Form type
- 4
- Filed
- Feb 15, 7:00 PM ET
- Accepted
- Feb 16, 8:17 AM ET
- Size
- 12.8 KB